PA8841901A1 - Compuestos orgánicos - Google Patents

Compuestos orgánicos

Info

Publication number
PA8841901A1
PA8841901A1 PA20098841901A PA8841901A PA8841901A1 PA 8841901 A1 PA8841901 A1 PA 8841901A1 PA 20098841901 A PA20098841901 A PA 20098841901A PA 8841901 A PA8841901 A PA 8841901A PA 8841901 A1 PA8841901 A1 PA 8841901A1
Authority
PA
Panama
Prior art keywords
organic compounds
compounds
fosfatidil
inositol
substitutes
Prior art date
Application number
PA20098841901A
Other languages
English (en)
Inventor
Alec Fairhurst Robin
Guagnano Vito
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40350060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8841901(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PA8841901A1 publication Critical patent/PA8841901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO DE LA FÓRMULA(I):O A UNA SAL DEL MISMO,EN DONDE LOS SUSTITUYENTES SON COMO SE DEFINEN EN LA DESCRIPCIÓN,A COMPOSICIONES Y AL USO DE LOS COMPUESTOS EN EL TRATAMIENTO DE ENFERMEDADES QUE MEJORAN MEDIANTE LA INHIBICIÓN DE LA CINASA DE FOSFATIDIL-INOSITOL-3
PA20098841901A 2008-09-10 2009-09-10 Compuestos orgánicos PA8841901A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164104 2008-09-10
US9667408P 2008-09-12 2008-09-12

Publications (1)

Publication Number Publication Date
PA8841901A1 true PA8841901A1 (es) 2010-06-28

Family

ID=40350060

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098841901A PA8841901A1 (es) 2008-09-10 2009-09-10 Compuestos orgánicos

Country Status (49)

Country Link
US (4) US8227462B2 (es)
EP (1) EP2331537B1 (es)
JP (1) JP5486601B2 (es)
KR (1) KR101290844B1 (es)
CN (1) CN102149711B (es)
AR (2) AR073369A1 (es)
AU (1) AU2009290904B2 (es)
BR (1) BRPI0918750B8 (es)
CA (1) CA2734819C (es)
CL (1) CL2011000504A1 (es)
CO (1) CO6351738A2 (es)
CR (1) CR20110059A (es)
CU (1) CU24000B1 (es)
CY (2) CY1117078T1 (es)
DK (1) DK2331537T3 (es)
DO (1) DOP2011000070A (es)
EA (1) EA018863B1 (es)
EC (1) ECSP11010880A (es)
ES (1) ES2560673T3 (es)
GE (1) GEP20135991B (es)
HK (1) HK1156305A1 (es)
HN (1) HN2011000699A (es)
HR (1) HRP20160014T1 (es)
HU (2) HUE025884T2 (es)
IL (1) IL210976A (es)
JO (1) JO3121B1 (es)
LT (1) LTC2331537I2 (es)
MA (1) MA32604B1 (es)
ME (1) ME01284B (es)
MX (1) MX2011002597A (es)
MY (1) MY151556A (es)
NI (1) NI201100049A (es)
NL (1) NL301071I2 (es)
NO (1) NO2020037I1 (es)
NZ (1) NZ590754A (es)
PA (1) PA8841901A1 (es)
PE (1) PE20110796A1 (es)
PL (1) PL2331537T3 (es)
PT (1) PT2331537E (es)
RS (1) RS54476B1 (es)
SI (1) SI2331537T1 (es)
SM (1) SMP201100019B (es)
SV (1) SV2011003853A (es)
TN (1) TN2011000053A1 (es)
TW (1) TWI453206B (es)
UA (1) UA104147C2 (es)
UY (1) UY32096A (es)
WO (1) WO2010029082A1 (es)
ZA (1) ZA201100699B (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
EP2310050A1 (en) 2008-07-11 2011-04-20 Novartis AG Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
AU2015203865B2 (en) * 2010-11-08 2016-11-03 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
WO2012062694A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
UA112539C2 (uk) 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
NZ615593A (en) * 2011-04-25 2015-05-29 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
MX2013014887A (es) * 2011-06-21 2014-02-17 Novartis Ag Polimorfos de 1- ({4-metil-5- [2- (2 ,2 ,2-trifluoro-1,1-dimetil-e til) piridin-4-il] - tiazol-2-il}-amida de 2-amida del acido (s) -pirrolidin-1,2-dicarboxilico.
UA114178C2 (uk) 2011-07-01 2017-05-10 Новартіс Аг Комбінація, що включає інгібітор cdk4/6 і інгібітор pi3k, для лікування раку
JP6058009B2 (ja) * 2011-08-31 2017-01-11 ノバルティス アーゲー Ｐｉ３ｋ−およびｍｅｋ−阻害剤の相乗的な組合せ
WO2013049581A1 (en) * 2011-09-30 2013-04-04 Beth Israel Deaconess Medical Center Inc. Compositions and methods for the treatment of proliferative diseases
BR112014008400A2 (pt) * 2011-10-14 2017-04-04 Novartis Ag derivados de 2-carboxamida cicloamino ureia em combinação com os inibidores de hsp90 para o tratamento de doenças proliferativas
AU2012328979B2 (en) * 2011-10-28 2016-04-21 Novartis Ag Method of treating gastrointestinal stromal tumors
EP2776026A1 (en) 2011-11-02 2014-09-17 Novartis AG 2-carboxamide cycloamino urea derivatives for use in treating vegf - dependent diseases
KR102083041B1 (ko) 2012-02-22 2020-05-27 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 술폰아미드 화합물 및 ｔｎａｐ 억제제로서 용도
CN104271136A (zh) 2012-03-29 2015-01-07 诺华股份有限公司 药学诊断
JP2015512416A (ja) * 2012-03-30 2015-04-27 ノバルティス アーゲー 神経芽細胞腫、ユーイング肉腫または横紋筋肉腫の治療に使用するための化合物
KR20160027217A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy
LT2882440T (lt) * 2012-08-07 2019-04-25 Novartis Ag Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį
KR20210049187A (ko) * 2012-08-16 2021-05-04 노파르티스 아게 Pi3k 억제제와 c-met 억제제의 조합물
CA2880506C (en) 2012-09-20 2021-04-20 Novartis Ag Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor and an aromatase inhibitor
US9732032B2 (en) * 2012-11-16 2017-08-15 Merck Patent Gmbh 3-aminocyclopentane carboxamide derivatives
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
AU2014208964B2 (en) 2013-01-23 2016-09-01 Astrazeneca Ab Chemical compounds
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
AU2014233805B2 (en) * 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
RU2015142258A (ru) * 2013-04-05 2017-05-12 Санофи Противоопухолевая композиция, включающая pi3k бета-селективный ингибитор и pi3k альфа-селективный ингибитор
US20160095842A1 (en) 2013-05-31 2016-04-07 Christine Fritsch Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
US20160120871A1 (en) * 2013-06-11 2016-05-05 Novartis Ag Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
WO2014203152A1 (en) 2013-06-18 2014-12-24 Novartis Ag Pharmaceutical combinations
US20160175293A1 (en) 2013-08-08 2016-06-23 Novartis Ag Pim kinase inhibitor combinations
PT3033086T (pt) 2013-08-14 2021-12-15 Novartis Ag Terapia de combinação para o tratamento de cancro
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
PL3076969T3 (pl) * 2013-12-06 2022-01-17 Novartis Ag Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy
MX2016009226A (es) * 2014-01-15 2016-10-05 Novartis Ag Combinaciones farmaceuticas.
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20170165246A1 (en) 2014-02-11 2017-06-15 Novartis Ag Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
AU2015326392B2 (en) 2014-10-03 2018-10-04 Novartis Ag Pharmaceutical compositions comprising alpelisib
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
CN104844589B (zh) * 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
KR20170129802A (ko) 2015-03-10 2017-11-27 아두로 바이오테크, 인코포레이티드 ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
WO2016151501A1 (en) 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
CA2981159A1 (en) 2015-06-29 2017-01-05 F. Hoffmann-La Roche Ag Methods of treatment with taselisib
EP3567045B1 (en) 2015-07-02 2022-01-12 F. Hoffmann-La Roche AG Benzoxazepin oxazolidinone compounds and methods of use
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3340986A1 (en) 2015-08-28 2018-07-04 Novartis AG A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
EP3380097A2 (en) 2015-08-28 2018-10-03 Novartis AG Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer
WO2017037574A1 (en) 2015-08-28 2017-03-09 Novartis Ag Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
EP3340987A1 (en) 2015-08-28 2018-07-04 Novartis AG Combination of ribociclib and dabrafenib for treating or preventing cancer
WO2017037586A1 (en) 2015-08-28 2017-03-09 Novartis Ag Combination therapy using pi3k inhbitor and mdm2 inhibitor
AU2016314082B2 (en) 2015-08-28 2019-07-25 Novartis Ag Mdm2 inhibitors and combinations thereof
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
CN105294546B (zh) * 2015-10-29 2017-12-08 天津市斯芬克司药物研发有限公司 一种吡啶化合物及其制备方法
CA3002954A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
MX2018006777A (es) 2015-12-03 2018-08-01 Novartis Ag Tratamiento de cancer con un inhibidor de pi3k en un paciente previamente seleccionado por tener una mutacion de pik3ca en el ctadn.
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN106674200B (zh) * 2016-12-21 2019-04-12 西安交通大学 一种含有l-脯氨酰胺片段的化合物及其制备方法和应用
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
EP3713963A1 (en) 2017-11-23 2020-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2019106604A1 (en) 2017-12-01 2019-06-06 Novartis Ag Pharmaceutical combination comprising lsz102 and alpelisib
MX2020005753A (es) * 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
KR20210018304A (ko) 2018-05-30 2021-02-17 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 트리사이클릭 유도체를 함유하는 억제제, 이를 위한 제조 방법, 및 이의 적용
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020053125A1 (en) * 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of neurofibromatosis
US20210353607A1 (en) * 2018-10-05 2021-11-18 Sloan-Kettering Institute For Cancer Research Pi3k inhibitors and uses thereof
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN113874362A (zh) 2019-05-13 2021-12-31 罗欣健康科技发展(北京)有限公司 喹唑啉酮类化合物的晶型及其制备方法
CN111995541A (zh) * 2019-05-27 2020-11-27 润佳（苏州）医药科技有限公司 含有稳定重同位素的酰胺官能团的化合物及其应用
WO2021001427A1 (en) 2019-07-02 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis
WO2021001431A1 (en) 2019-07-02 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer
WO2021001426A1 (en) 2019-07-02 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ultrafast elasticity imaging for detecting pancreatic cancers
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
AU2020389670A1 (en) 2019-11-25 2022-05-19 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof
CN113045564A (zh) * 2019-12-27 2021-06-29 上海天慈国际药业有限公司 一种阿培利司的制备方法
AU2021244786A1 (en) * 2020-03-25 2022-11-03 Risen (Suzhou) Pharma Tech Co., Ltd. Stable heavy isotopes in amide functional groups and uses thereof
WO2022016420A1 (zh) * 2020-07-22 2022-01-27 罗欣药业(上海)有限公司 一种喹唑啉酮类化合物的晶型、其制备方法及应用
EP4333812A1 (en) 2021-05-03 2024-03-13 Novartis AG Alpelisib formulation
WO2023083330A1 (zh) * 2021-11-12 2023-05-19 百极优棠(广东)医药科技有限公司 Drak2抑制剂及其制备方法和应用
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
WO2024089272A1 (en) 2022-10-28 2024-05-02 Institut National De La Sante Et De La Recherche Medicale New inhibitors of phosphatidylinositol 3-kinase

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649146A (en) * 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
DE3703435A1 (de) 1987-02-05 1988-08-18 Thomae Gmbh Dr K Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5229402A (en) 1988-04-15 1993-07-20 Taiho Pharmaceutical Company, Ltd. Carbamoyl-2-pyrrolidinone compounds
US5028726A (en) * 1990-02-07 1991-07-02 The University Of Vermont And State Agricultural College Platinum amine sulfoxide complexes
US5780653A (en) * 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
EP0946587A2 (en) 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
ATE427353T1 (de) * 1997-02-10 2009-04-15 Genentech Inc Heregulin varianten
US6436966B1 (en) 1997-10-27 2002-08-20 Takeda Chemical Ind., Ltd. Adenosine A3 receptor antagonists
JP2002518380A (ja) 1998-06-18 2002-06-25 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤
ATE309241T1 (de) * 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
CN100496493C (zh) * 2001-08-13 2009-06-10 詹森药业有限公司 2-氨基-4,5-三取代噻唑基衍生物
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1760082A1 (en) * 2001-09-28 2007-03-07 Cyclacel Limited N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as anti-proliferative compounds
PE20030968A1 (es) * 2002-02-28 2004-01-12 Novartis Ag Derivados de 5-feniltiazol como inhibidores de cinasas
AU2003288956A1 (en) * 2002-10-30 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
AU2004204778B2 (en) * 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
JP2007504255A (ja) * 2003-09-06 2007-03-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ａｔｐ結合カセットトランスポーターの調節因子
ZA200605624B (en) 2004-01-12 2007-11-28 Applied Research Systems Thiazole derivatives and use thereof
AU2005260032A1 (en) * 2004-06-29 2006-01-12 Amgen Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity
SE0402735D0 (sv) * 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
CA3054535A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
DE102005024157A1 (de) 2005-05-23 2006-11-30 Amedo Gmbh Nadelpositioniersystem
BRPI0610341A2 (pt) 2005-05-24 2010-06-15 Serono Lab derivados de tiazol e uso dos mesmos
BRPI0611029A2 (pt) 2005-05-24 2010-08-10 Serono Lab derivados de tiazol e uso dos mesmos
DE102005024790A1 (de) 2005-05-26 2006-12-07 Eos Gmbh Electro Optical Systems Strahlungsheizung zum Heizen des Aufbaumaterials in einer Lasersintervorrichtung
US7655446B2 (en) * 2005-06-28 2010-02-02 Vertex Pharmaceuticals Incorporated Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
ZA200805227B (en) 2005-12-12 2009-11-25 Genelabs Tech Inc N-(5-memebered heteroarmatic ring)-amido anti-viral compounds
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
JP2009523769A (ja) * 2006-01-23 2009-06-25 ラボラトワール セローノ ソシエテ アノニム チアゾール誘導体及びこれらの使用
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
CN101484452A (zh) * 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 噻唑衍生物及其作为抗肿瘤药物的用途
GB0610243D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
GB0612630D0 (en) * 2006-06-26 2006-08-02 Novartis Ag Organic compounds
FR2904190B1 (fr) 2006-07-25 2008-12-12 Inst Rech Pour Le Dev I R D Et Utilisation d'inocula fongiques pour l'amelioration de la production maraichere
TW200827368A (en) 2006-11-21 2008-07-01 Genelabs Tech Inc Amido anti-viral compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
CN101687790B (zh) 2007-05-25 2015-02-11 Abbvie公司 作为代谢型谷氨酸受体2(mglu2受体)的正向调节剂的杂环化合物
WO2009003009A1 (en) 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Substituted pyrrolidine as anti-infectives
AU2008275891B2 (en) 2007-07-19 2013-10-10 H.Lundbeck A/S 5-membered heterocyclic amides and related compounds
US20100298286A1 (en) 2007-12-20 2010-11-25 Novartis Ag Organic Compounds
ITMI20072396A1 (it) 2007-12-20 2009-06-21 Dachi S R L "apparato di chiusura di contenitori di materiale biologico"
JP2011506560A (ja) * 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

Also Published As

Publication number Publication date
TN2011000053A1 (en) 2012-09-05
UY32096A (es) 2010-04-30
KR101290844B1 (ko) 2013-07-29
NL301071I1 (nl) 2020-11-11
EP2331537A1 (en) 2011-06-15
CA2734819A1 (en) 2010-03-18
NZ590754A (en) 2012-08-31
DOP2011000070A (es) 2011-03-31
US8476268B2 (en) 2013-07-02
US20120263712A1 (en) 2012-10-18
SI2331537T1 (sl) 2016-02-29
NO2020037I1 (no) 2020-11-16
BRPI0918750B1 (pt) 2020-12-22
BRPI0918750B8 (pt) 2021-05-25
EA018863B1 (ru) 2013-11-29
BRPI0918750A2 (pt) 2020-08-04
MY151556A (en) 2014-06-13
US8710085B2 (en) 2014-04-29
CY2020037I1 (el) 2021-03-12
ZA201100699B (en) 2012-08-29
ES2560673T3 (es) 2016-02-22
GEP20135991B (en) 2013-12-25
DK2331537T3 (en) 2016-01-25
JP5486601B2 (ja) 2014-05-07
PT2331537E (pt) 2016-03-03
MX2011002597A (es) 2011-07-21
US20140005232A1 (en) 2014-01-02
CA2734819C (en) 2017-10-24
JO3121B1 (ar) 2017-09-20
CU24000B1 (es) 2014-06-27
CN102149711B (zh) 2014-09-10
EP2331537B1 (en) 2015-10-28
ECSP11010880A (es) 2011-04-29
UA104147C2 (uk) 2014-01-10
LTC2331537I2 (lt) 2022-01-10
CR20110059A (es) 2011-03-28
PE20110796A1 (es) 2011-11-04
IL210976A0 (en) 2011-04-28
SV2011003853A (es) 2011-05-16
HUS2000044I1 (hu) 2020-12-28
CN102149711A (zh) 2011-08-10
AR073369A1 (es) 2010-11-03
JP2012502080A (ja) 2012-01-26
LTPA2020534I1 (lt) 2020-12-28
AR112074A2 (es) 2019-09-18
SMP201100019B (it) 2012-01-18
SMAP201100019A (it) 2011-05-06
US20100105711A1 (en) 2010-04-29
WO2010029082A1 (en) 2010-03-18
CO6351738A2 (es) 2011-12-20
CU20110052A7 (es) 2011-12-28
RS54476B1 (en) 2016-06-30
TW201014851A (en) 2010-04-16
HRP20160014T1 (hr) 2016-02-12
HK1156305A1 (en) 2012-06-08
NI201100049A (es) 2011-07-26
HUE025884T2 (en) 2016-05-30
HN2011000699A (es) 2013-12-02
US8227462B2 (en) 2012-07-24
ME01284B (me) 2013-06-20
TWI453206B (zh) 2014-09-21
US20140186469A1 (en) 2014-07-03
CY2020037I2 (el) 2021-03-12
NL301071I2 (nl) 2020-12-01
EA201100447A1 (ru) 2011-10-31
AU2009290904A1 (en) 2010-03-18
MA32604B1 (fr) 2011-09-01
AU2009290904B2 (en) 2012-08-30
IL210976A (en) 2014-09-30
KR20110038737A (ko) 2011-04-14
CL2011000504A1 (es) 2011-07-15
PL2331537T3 (pl) 2016-06-30
CY1117078T1 (el) 2017-04-05

Similar Documents

Publication Publication Date Title
PA8841901A1 (es) Compuestos orgánicos
PA8740901A1 (es) Compuestos organicos
NI201100048A (es) Aminotriazolopiridinas y su uso como inhibidores de la cinasa.
CR20120264A (es) Compuestos
CR20110339A (es) Compuestos útiles para inhibir chk1
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
PA8809001A1 (es) Compuestos organicos
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
GT201400111A (es) Triazolopiridinas sustituidas
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CR20110264A (es) Pirazolilaminopiridinas como inhibidores de fak
UY31849A (es) Nuevos compuestos como inhibidores de pde4
PA8806801A1 (es) Compuestos de amida como refuerzos de antivirales
ECSP10010648A (es) Derivados de aminopiridina
UY32748A (es) 2-carboxamida-cicloamino-ureas
CO6341625A2 (es) Derivados de indol como agentes anticáncer
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas
DOP2009000214A (es) Macrolidos basados en eritromicina
GT201300044A (es) Composiciones alguicidas sinergicas que incluyen derivados de hidrazona y cobre
UY32360A (es) Compuestos de etanamina y métodos de utilización de los mismos 545
UY32447A (es) Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia
AR095353A1 (es) Compuesto